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Abstract
Limited information from human studies indicates that dietary quercetin supplementation influences blood lipid profiles, glycemic response, and 
inflammatory status, collectively termed cardiometabolic risks. We tested the hypothesis that quercetin-rich supplementation, derived from onion
peel extract, improves cardiometabolic risk components in healthy male smokers in a randomized, double blinded, placebo-controlled parallel design.
Randomly assigned subjects were instructed to take either the placebo (n = 43) or 100 mg quercetin capsules each day (n = 49) for 10 weeks. Anthropometric
parameters and blood pressure were measured, and blood lipids, glucose, interleukin-6, and soluble vascular cell adhesion molecule-1 (sVCAM-1) 
were determined at baseline and after 10 weeks of quercetin supplementation. Quercetin-rich supplementation significantly reduced serum concentrations
of total cholesterol (P < 0.05) and LDL-cholesterol (P< 0.01), whereas these effects were not shown in the placebo group. Furthermore, significant
increases were observed in serum concentrations of HDL-cholesterol both in the placebo (P < 0.005) and quercetin-rich supplementation group (P
< 0.001); however, changes in HDL-cholesterol were significantly greater in subjects receiving quercetin-rich supplementation than the placebo. Both
systolic (P< 0.05) and diastolic blood pressure (P< 0.01) decreased significantly in the quercetin-rich supplementation group. Glucose concentrations
decreased significantly after 10 weeks of quercetin-rich supplementation (P< 0.05). In contrast, no effects of quercetin-rich supplementation were 
observed for the inflammatory markers-IL-6 and sVCAM-1. Daily quercetin-rich supplementation from onion peel extract improved blood lipid profiles,
glucose, and blood pressure, suggesting a beneficial role for quercetin as a preventive measure against cardiovascular risk.
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Introduction4)
Data from epidemiological and clinical studies have indicated 
a relationship between dietary intake of flavonoids and reduced 
risk of cardiovascular disease [1-4], which is mainly ascribed 
to the compound’s in vitro antioxidant and anti-inflammatory 
effects [5]. Onions are a major source of dietary flavonoids 
including quercetin, rutin, and myricetin. In particular, quercetin 
has been suggested as the most potent compound displaying 
antioxidant effects [6]. Quercetin scavenges oxygen free radicals, 
inhibits lipid peroxidation, and quenches 8-hydroxydeoxyguanosine 
formation by ultraviolet light irradiation and the Fenton reaction 
[7], which subsequently protects cellular macromolecules against 
oxidative damage. Quercetin also inhibits the ex vivo resistance 
of low-density lipoprotein (LDL) to oxidation and resistance to 
DNA strand breakage induced by hydrogen peroxide in human 
lymphocytes [8,9].
A number of experimental and in vitro studies have reported 
that quercetin possesses several other beneficial activities, 
including hypolipidemic [10-12], antihypertensive [13], anti- 
inflammatory [14,15], and antithrombotic actions [16].
  However, 
as reported in a recent review [17], the effects of dietary quercetin 
on cardiovascular disease biomarkers in human studies have been 
inconsistent based on study design, type of compound (pure or 
food source), study duration, dosage, and the phenotypes of the 
study subjects. Moreover, limited information is available from 
human studies as to whether dietary quercetin supplementation 
influences blood lipid profiles, glycemic response, and inflammatory 
status, collectively termed cardiometabolic risks. 
Therefore, we comprehensively tested the hypothesis that 
quercetin-rich supplementation, derived from onion peel extract, 
influences cardiometabolic risk components including blood 
pressure, blood lipid profiles and the concentrations of glucose 
and inflammatory cytokines in male smokers who confer 
relatively higher risks for cardiovascular disease. The results will 
provide additional information on the effects of dietary quercetin 
supplementation on cardiometabolic risk components as a 
preventive measure.
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Subjects and Methods
Study subjects
The total study population consisted of 92 healthy volunteers. 
The inclusion criteria were male smokers in the age range of 30- 
60-years. All subjects were healthy, and those with documented 
type 2 diabetes mellitus, hypertension, thyroid disorders, malab-
sorption syndrome, or any type of coronary heart disease were 
excluded. Furthermore, subjects who were taking any medications 
known to influence the variables to be studied were excluded. 
Body mass index (BMI) was calculated as weight in kg divided by 
height in meters squared; waist circumference was also measured. 
Blood pressure was measured from the left arm in seated patients 
with an automatic blood pressure monitor (TM-2654, A & D, 
Tokyo, Japan) after a 20 min rest. Two measurements were taken 
at least 5 minutes apart, and the mean was used for analysis. 
The subjects were given written informed consent, and the 
institutional review board at Hannam University approved the 
study protocol. 
Study protocol and blood collection
This study consisted of 7 days of quercetin depletion followed 
by a 10-week supplementation period in a randomized, double 
blinded, placebo-controlled parallel design. During the quercetin 
depletion period, all subjects were requested to restrict their 
consumption of quercetin to avoid any influence on the study 
results. These food ingredients included onions, apples, red wine, 
tea, biological and freshly pressed fruit juices, berries, grapes, 
cherries, raisins, parsley, broccoli, cabbage, beans, and tomatoes. 
Subsequently, the subjects were randomly assigned to either a 
placebo group (n = 43) or a quercetin-rich supplementation group 
(n = 49). The subjects were instructed to take either four capsules 
of placebo (dextrin) or four quercetin capsules per day containing 
100 mg quercetin dihydrate and 128 mg other mixed flavonoids 
(composition unknown). To prepare the quercetin-rich supple-
mentation capsules, onion peels purchased from Nonghyup 
located in Changnyeong, were washed three times in tap water 
and extracted with a 60% aqueous ethanol solution (50℃, 3 hrs) 
in a extractor (1 kL, Hansung F & C Co., Ltd., Seoul, Korea). 
The extracts were filtered with a filter press (Hankook Industry 
Co. Ltd., Seoul, Korea), the filtrates were concentrated to 2.4
o 
Brix in a vacuum concentrator (1 kL, Hansung F & C Co), and 
then the concentrates were processed to powder with a freeze 
dryer (SFDTS-200 kg Samwon Industry Co., Ltd. Seoul, Korea). 
Finally, the powder was adjusted to contain 100 mg quercetin/g 
dextrin (Samyang Co., Seoul, Korea). The subjects were 
instructed to maintain their usual patterns of dietary intake during 
the study. Compliance was monitored through biweekly phone 
calls for capsule counts, and a nutritionist checked for changes 
in usual dietary patterns at the end of the study. Additionally, 
the subjects’ usual dietary intakes were assessed both at baseline 
and at 10 weeks after quercetin-rich supplementation using a 24-h 
recall method. Nutrient intake levels were determined as mean 
values from a 3-day food record using CAN pro (Korean 
Nutrition Society, Seoul, Korea) based on the food composition 
table of the National Rural Living Science Institute in Korea 
and other published data [18,19]. Venous blood samples were 
collected from the forearm in EDTA-treated and plain tubes after 
a fasting period, both at baseline and at 10 weeks after the 
intervention. 
Serum lipid, lipoprotein, and glucose concentrations 
Serum cholesterol, LDL cholesterol, and HDL cholesterol were 
measured with commercially available kits (Choongwae, Seoul, 
Korea) using enzymatic methods. Serum triglyceride was analyzed 
using a total glycerol test kit (Roche, Basel, Switzerland). All 
measurements were performed on a Hitachi 747 autoanalyzer 
(Hitachi Ltd, Tokyo, Japan). Fasting serum glucose concentrations 
were measured by the glucose oxidase method using a Beckman 
glucose analyzer (Beckman Instruments, Irvine, CA, USA). 
Plasma IL-6 and sVCAM-1 concentrations 
Plasma interleukin-6 (IL-6, R & D Systems, Minneapolis, MN, 
USA) and soluble vascular cell adhesion molecule-1 (sVCAM-1, R 
& D Systems) were measured using an enzyme-linked immunoassay, 
according to the manufacturer’s instructions. 
Statistical analysis
SPSS 12.0 (SPSS Inc, Chicago, IL, USA) was used for the 
statistical analysis. The data are presented as means ± SD. Each 
variable was examined for a normal distribution, and abnormally 
distributed variables were log-transformed. Pearson’s correlation 
coefficients were used to evaluate relationships between variables. 
For the within-group test, we conducted paired t-tests for the 
biochemical parameters before and after the 10-week intervention. 
For the between-group test, differences in clinical parameters 
between the two groups were analyzed using the Student’s t-test. 
P values < 0.05 were considered statistically significant.
Results
Subject characteristics 
All 92 male subjects [mean age, 44.3 yrs; placebo group, n
= 43; quercetin-rich supplementation group, n = 49] completed 
the study (Table 1). The mean age of the quercetin-rich 
supplementation group was greater than that of the placebo 
group; although the difference was small, it was significant. At 
the start of the study, BMIs were similar but waist circumferences 
were different between the two groups. Compliance was high 30 Quercetin and cardiometabolic risks in smokers
Placebo (n = 43) Quercetin-rich supplementation (n = 49)
P-value
2)
Baseline 10 wks P-value
1) Baseline 10 wks P-value
1)
Age (yrs) 42.4 ± 8.2 [23-55] 46.1 ± 7.1 [32-62] < 0.05
Body mass index (kg/m
2) 24.9 ± 2.8 24.7 ± 2.9 NS 24.7 ± 3.0 24.8 ± 2.9 NS NS
Waist circumference (cm) 89.6 ± 5.7 88.1 ± 6.5 < 0.05 80.4 ± 7.2 79.9 ± 6.3 NS < 0.001
Values  are  mean ± SD.
1) P-values  for  the  comparison  between  baseline  and  the  10  wk  intervention  were  obtained  using  paired  t-tests  in  each  group.
2) P-values  for  comparison  between  the  placebo  and  quercetin-rich  supplementation  groups  at  baseline  were  made  using  the  Student’s  t-test.
Table 1. Age and anthropometric measurements in the subjects before and after 10 weeks of quercetin supplementation
Placebo (n = 43) Quercetin-rich supplementation (n = 49)
P-value
2)
Baseline 10 wks P-value
1) Baseline 10 wks P-value
1)
Total cholesterol (mg/dL) 194.3 ± 36.4 196.2 ± 37.5 NS 193.5 ± 32.1 185.2 ± 31.3 < 0.05 NS
Triglyceride (mg/dL) 185.0 ± 91.6 171.0 ± 121.1 NS 163.5 ± 87.7 156.9 ± 99.3 NS NS
HDL-cholesterol (mg/dL) 45.0 ± 5.3 47.3 ± 6.5 < 0.005 44.3 ± 6.9 51.4 ± 6.5 < 0.001 NS
LDL-cholesterol (mg/dL) 115.6 ± 24.7 116.9 ± 25.6 NS 113.2 ± 20.3 106.5 ± 19.1 < 0.01 NS
Glucose (mg/dL) 109.9 ± 28.5 109.4 ± 24.5 NS 108.3 ± 18.1 104.1 ± 17.5 < 0.05 NS
Values  are  mean ± SD.
1) P-values  for  comparison  between  baseline  and  the  10  wk  intervention  were  obtained  using  paired  t-tests  in  each  group.
2) P-values  for  comparing  between  the  placebo  and  quercetin-rich  supplementation  groups  at  baseline  were  made  using  the  Student’s  t-test.
Table 2. Blood lipid profile and glucose measurements before and after 10 weeks of quercetin supplementation
Placebo (n = 43) Quercetin-rich supplementation (n = 49)
P-value
2)
Baseline 10 wks P-value
1) Baseline 10 wks P-value
1)
Systolic blood pressure (mmHg) 135.5 ± 11.3 132.5 ± 12.7 NS 132.9 ± 14.9 129.3 ± 13.3 < 0.05 NS
Diastolic blood pressure (mmHg) 86.9 ± 10.4 84.0 ± 9.2 NS 88.7 ± 9.9 85.5 ± 10.0 < 0.01 NS
IL-6 (pg/mL) 1.25 ± 0.44 1.31 ± 0.48 NS 1.26 ± 0.44 1.29 ± 0.44 NS NS
sVCAM -1 (ng/mL) 4.78 ± 0.34 4.72 ± 0.28 NS 4.85 ± 0.35 4.81 ± 0.29 NS NS
Values  are  mean ± SD.
IL-6:  interleukin-6;  sVCAM  -1  :  soluble  vascular  cell  adhesion  molecule-1 
1) P-values  for  comparison  between  baseline  and  10-wk  intervention  were  made  using  the  paired  t-test  in  each  group.
2) P-values  for  comparing  the  placebo  and  the  quercetin-rich  supplementation  group  were  made  at  baseline  using  the  Student’s  t-test.
Table 3. Blood pressure and inflammatory cytokine concentrations before and after 10 weeks of quercetin supplementation
and the subjects took 96% of the provided capsules with no 
differences between the groups. No adverse effects due to 
quercetin intake were reported. At baseline, the estimated average 
total caloric intake of all subjects was 2,040 kcal (% CHO:% 
PRO:% FAT = 55:17:25), and at 10 weeks of intervention it was 
2,002 kcal (% CHO:% PRO:% FAT = 54:18:23). As shown in 
Table 1, a significant change in waist circumference was 
observed in the placebo group (P< 0.05), whereas this result was 
not shown in the quercetin-rich supplementation group.
Lipid and lipoprotein concentrations
Table 2 describes the changes in lipids and lipoproteins after 
10 wk of quercetin supplementation. Serum concentrations of 
total cholesterol (P < 0.05) and LDL-cholesterol (P <0 . 0 1 )  
decreased significantly; however, these effects were not shown 
in the placebo group. Additionally, significant increases in serum 
concentrations of HDL-cholesterol (P < 0.001) were observed 
after 10 weeks of quercetin-rich supplementation, whereas 
significant increases in HDL-cholesterol were also observed in 
the placebo group (P < 0.005). However, the changes in HDL- 
cholesterol in the placebo and quercetin-rich supplementation 
groups (2.3 ± 4.9 vs. 7.1 ± 5.1 mg/dL, P< 0.001) were significantly 
greater in the quercetin-rich supplementation group than the 
placebo group. In contrast, no differences were observed in serum 
TG concentrations in the placebo and the quercetin-rich 
supplementation groups.
Blood pressure and glucose concentrations
Serum concentrations of glucose decreased significantly (P < 
0.05) after 10 weeks of supplementation, whereas these effects 
were not shown in the placebo group (Table 2). Furthermore, 
both systolic (P < 0.05) and diastolic blood pressure (P <0 . 0 1 )  
dropped significantly in the quercetin-rich supplementation group 
(Table 3). 
Inflammatory cytokines
No significant changes in the concentrations of IL-6 and 
sVCAM-1 were observed after 10 weeks of quercetin-rich 
supplementation (Table 3).Kyung-Hea Lee et al. 31
Discussion
Cardiometabolic risks represent a constellation of cardio-
vascular and metabolic abnormalities that interact to increase the 
risk for morbidity and mortality from cardiovascular disease and 
type 2 diabetes mellitus [20,21]. The prevalence of cardiometabolic 
risks has been increasing and represents a public health concern; 
thus, therapeutic lifestyle changes and dietary supplements to 
modify the cardiometabolic risks need to be encouraged. In the 
present study, we tested whether quercetin-rich supplementation 
derived from onion peel extract would favorably influence blood 
lipids, blood pressure, glycemic response, and inflammatory 
markers. The results showed that blood pressure and glucose 
concentrations decreased significantly after 10 weeks of inter-
vention. Additionally, quercetin-rich supplementation reduced serum 
concentrations of total cholesterol and increased serum concentra-
tions of HDL-cholesterol, whereas no effect was observed for 
serum TG concentrations. Also, quercetin-rich supplementation did 
not affect the concentrations of the proinflammatory cytokines 
IL6 and sVCAM-1.
A prospective study reported that the consumption of dietary 
quercetin is inversely associated with total mortality and 
cardiovascular mortality [22]. Among the mechanisms explaining 
these associations include the effects of quercetin on lipid 
metabolism [10-12], oxidative stress [6], and inflammation 
[14,15]. Several plausible pathways as to how quercetin affects 
lipid metabolism have been suggested by animal studies. 
Quercetin increases fecal excretion of cholesterol and bile acids, 
thereby, decreasing serum cholesterol levels and total liver 
cholesterol content in rats [12]. Kamada et al. [11] reported that 
quercetin glucoside significantly reduces the amounts of total 
cholesterol, triacylglycerol, and total fatty acids in both the 
plasma and aortas of rats fed a high cholesterol diet. Additionally, 
recent experimental data further supports the hypolipidemic effect 
of quercetin. Gnoni et al. [23] demonstrated that quercetin 
induces reductions in both de novo fatty acid and TG synthesis 
and the resulting decreases in VLDL-TG formation in hepatocytes 
of normal rats suggests a cardioprotective role for dietary 
quercetin. These results indicate that quercetin may be involved 
in lipid metabolism in rats by reducing hepatic fatty acid 
synthesis and by inhibiting cholesterol biosynthesis [24]. 
However, the hypolipidemic effects of quercetin in human 
clinical studies have been inconclusive. Supplements of 
quercetin-rich onion powder [25], grape juice [26], and grape 
powder [27] favorably influence blood lipid profiles in humans. 
In addition to the results of controlled clinical studies, 
epidemiological evidence indicates that dietary quercetin intake 
is negatively associated with plasma levels of LDL-cholesterol 
after adjusting for total energy intake, dietary cholesterol intake, 
age, and BMI [28]. In contrast, as shown by Egert [29], a 2-week 
supplementation with quercetin did not change blood lipid 
concentrations in healthy humans. It was also reported that 
quercetin supplementation increases plasma quercetin concentrations 
without any effect on blood lipids [30], which is consistent with 
very recently published data [31]. In the present study, 
supplementation with quercetin from onion peel extract for 10 
weeks significantly reduced serum concentrations of total 
cholesterol and LDL-cholesterol and significantly increased 
serum concentrations of HDL-cholesterol in male smokers. These 
differences can be attributed to the duration of administration, 
the characteristics of the study subjects, and the amount and/or 
food sources of ingested quercetin. It is likely that the 10-week 
study period was long enough to demonstrate such effects of 
quercetin on the studied parameters. Furthermore, our subjects 
were all males and current smokers who were at increased 
cardiovascular risk. Smokers are under a high and sustained free 
radical load, which may overwhelm the antioxidant defense 
system, resulting in oxidative damage [32]. Additionally, the 
associations between chronic cigarette smoking and hypertension 
and low grade chronic inflammation and endothelial dysfunction 
are well recognized [33]. While the exact mechanism by which 
flavonoids, particularly quercetin, influences the cardiometabolic 
risk components has not been elucidated, a biological smoking 
interaction may be working to increase quercetin bioavailability 
in smokers who confer relatively higher risks for cardiovascular 
disease. Therefore, it would appear that smokers in particular, 
may benefit from quercetin supplementation. Currently, the 
prevalence of smoking is estimated at 47.7% in men. Although 
the prevalence of smoking among Korean men was 64.9% in 
1998 and has since declined, it still remains very high [34]. 
Considering that smoking is one of the major independent risk 
factors for cardiovascular disease [35], these results indicate that 
daily quercetin supplementation provides beneficial effects on 
blood lipid profile measurements, especially in smokers who are 
exposed to a high degree of oxidative stress and are particularly 
susceptible to the development of coronary heart disease.
Several studies have demonstrated that quercetin lowers blood 
pressure in hypertensive animals [13,36,37], which can be 
primarily attributed to its ability to modulate oxidative stress. 
Human intervention studies examining the blood lowering effects 
of quercetin have reported controversial data. While antihypertensive 
effects of quercetin have been reported [31,38], other interventions 
failed to show any positive effect of dietary quercetin supplementation 
[30], suggesting that a certain degree of hypertension may be 
required for quercetin to exert a blood pressure lowering effect. 
Although patients with documented hypertension were excluded, 
79% of all subjects were classified as prehypertensive or stage 
1 hypertensive in the present study. Consistent with earlier studies 
[31,38], significant reductions in systolic blood pressure by 3.5 
mmHg and diastolic blood pressure by 3.2 mmHg were observed 
following quercetin-rich supplementation, providing additional 
information on the antihypertensive effects of quercetin in 
individuals with relatively high blood pressure. 
We found that a 10 week quercetin-rich supplementation 
significantly decreased serum concentrations of glucose. In 
animal models, quercetin is effective for preventing a total loss 32 Quercetin and cardiometabolic risks in smokers
of  β-cell mass [39] and may ameliorate the symptoms of 
streptozotocin-induced diabetes by decreasing oxidative stress 
[40]. Furthermore, our results agree with a recent experimental 
report stating that high dose quercetin administration reduces 
glucose, dyslipidemia, and hypertension in an obese Zucker rat 
model of metabolic syndrome [41]. The mechanisms by which 
quercetin displays antidiabetic effects are not yet fully 
understood, but it is possible that the antioxidant properties of 
this compound may be involved in this effect. 
In contrast to previous in vitro results [14,15], no effects of 
quercetin-rich supplementation were observed for the proinfla-
mmatory cytokines IL-6 and sVCAM-1. This may, in part, be 
explained by the duration of intervention and/or dosage, which 
were not enough to elicit measurable effects, so further human 
studies to examine the anti-inflammatory effects of quercetin are 
needed.
Taken together, quercetin-rich supplementation from onion 
peel extract improved dyslipidemia, hypertension, and high 
glucose concentrations in male smokers but showed no effect 
on inflammation. Our results support the hypothesis that dietary 
quercetin from onion may play a cardioprotective role by 
modulating cardiometabolic risk factors.
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